Human T-lymphotropic virus 1 neurologic disease

Current Treatment Options in Neurology

Volumn 10, Issue 3, 2008, Pages 193-200

  Araújo, Abelardo ^a   Lima, Marco Antonio ^b   Silva, Marcus Tulius T ^b  

^a Funda??o Oswaldo Cruz   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMITRIPTYLINE; ANTIRETROVIRUS AGENT; BACLOFEN; BETA INTERFERON; BOTULINUM TOXIN; CARBAMAZEPINE; CORTICOSTEROID; CYCLOSPORIN; DANAZOL; DIAZEPAM; DOXAZOSIN; GABAPENTIN; GREEN TEA EXTRACT; IMIPRAMINE; LAMIVUDINE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYBUTYNIN; PENTOXIFYLLINE; PREDNISONE; PROBIOTIC AGENT; RIBAVIRIN; THEOPHYLLINE; TIZANIDINE; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE;

ACNE; ADRENAL INSUFFICIENCY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; APLASTIC ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE THYROIDITIS; BLADDER CATHETERIZATION; BONE MARROW SUPPRESSION; CHILD CARE; CORTICOSTEROID THERAPY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DYSPEPSIA; EPIDERMOLYSIS; FLU LIKE SYNDROME; GASTRITIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEPATITIS; HEPATITIS B; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; HYPERAMMONEMIA; HYPONATREMIA; INJECTION SITE DISCOLORATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INSOMNIA; IRRITABILITY; LACTIC ACIDOSIS; LACTOBACILLUS CASEI; LEUKOENCEPHALOPATHY; LIVER FIBROSIS; LIVER FUNCTION; LIVER TOXICITY; LOW BACK PAIN; MAINTENANCE THERAPY; MENSTRUATION DISORDER; MOTOR DYSFUNCTION; MOUTH ULCER; MUSCLE CRAMP; MYOPATHY; MYOSITIS; NAUSEA; NEUROPATHIC PAIN; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PEPTIC ULCER; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; PNEUMONIA; PSYCHOSIS; RESTLESSNESS; REVIEW; RHABDOMYOLYSIS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SPASTIC PARAPLEGIA; SPASTICITY; STEVENS JOHNSON SYNDROME; STRETCHING EXERCISE; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; URINARY DYSFUNCTION; VIRUS LOAD; VOMITING; WEIGHT GAIN;

EID: 56349143770     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0021-1     Document Type: Review

References (27)

1. Araújo A, Silva MTT: The HTLV-1 neurological complex. Lancet Neurol 2006, 5:1068-1076.
2. Silva MTT, Harab RC, Leite AC, et al.: Human T lymphotropic virus type 1 (HTLV-1) proviral load in asymptomatic carriers, HTLV-1-associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV-1 infection. Clin Infect Dis 2007, 44:689-692.
3. Cartier L, Cea JG, Vergara C, et al.: Clinical and neuropathological study of six patients with spastic paraparesis associated with HTLV-I: an axomyelinic degeneration of the central nervous system. J Neuropathol Exp Neurol 1997, 56:403-413.
4. Iwasaki Y, Ohara Y, Kobayashi I, Akizuki S: Infiltration of helper/ inducer T lymphocytes heralds central nervous system damage in human T-cell leukemia virus infection. Am J Pathol 1992, 140:1003-1008.
5. Nakagawa M, Nakahara K, Maruyama Y, et al.: Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 1996, 2:345-355.
6. Araújo AQ, Afonso CR, Leite AC, Dultra SV: Intravenous methylprednisolone in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Arq Neuropsiquiatr 1993, 51:325-328.
7. Yamasaki K, Kira J, Koyanagi Y, et al.: Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study. J Neurol Sci 1997, 147:135-144.
8. Izumo S, Goto I, ltoyama Y, et al.: Interferon-alpha is effective in HTLV-I-associated myelopatby: a multicenter, randomized, double-blind, controlled trial. Neurology 1996, 46:1016-1021.
9. Kuroda Y, Kurohara K, Fujiyama F, et al.: Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy. Acta Neurol Scand 1992, 86:82-86.
10. Isono T, Ogawa K, Seto A: Antiviral effect of zidovudine in the experimental model of adult T-cell leukaemia in rabbits. Leukaemia Research 1990, 14:841-847.
11. Gout O, Gessain A, Iba-Zizen M, et al.: The effect of zidovudine on chronic myelopathy associated with HTLV-1. J Neurol 1991, 238:108-109.
12. Sheremata WA, Benedict BS, Squilacote DC, et al.: High-dose zidovudine induction in HTLV-I associated myelopathy: safety and possible efficacy. Neurology 1993, 43:2125-2129.
13. Taylor GP, Hall SE, Navarrete S, et al.: Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-Tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol 1999, 73:10289-10295.
14. Taylor G, Goon P, Furukawa Y, et al.: Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopatliy: a randomised trial. Retrovirology 2006, 3:63.
15. Nakamura T, Shirabe S, Ichinose K, et al.: Pentoxifylline treatment in HTLV-I-associated myelopathy [letter]. Intern Med 1995, 34:460.
16. Shirabe S, Nakamura T, Tsujino A, et al.: Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy. J Neurol Sci 1997, 151:97-101.
17. Harrington WJ, Sheremata WA, Snodgrass SR, et al.: Tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol. AIDS Res Hum Retroviruses 1991, 7:1031-1034.
18. Melo A, Moura L, Meireles A, Costa G: Danazol. A new perspective in the treatment of HTLV-1 associated myelopathy (preliminary report). Arq Neuropsiquiatr 1992, 50:402-403.
19. Cronstein BN: Going with the flow: methotrexate, adenosine, and blood flow. Ann Rheum Dis 2006, 65:421-422.
20. Li HC, Yashiki S, Sonoda J, et al.: Green tea polyphenols induce apoptosis in vitro in peripheral blood T lymphocytes of adult T-cell leukemia patients. Jpn J Cancer Res 2000, 91:34-40.
21. Sonoda J, Koriyama C, Yamamoto S, et al.: HTLV-1 provirus load in peripheral blood lymphocytes of HTLV-1 carriers is diminished by green tea drinking. Cancer Sci 2004, 95:596-601.
22. Kato I, Yokokura T, Mutai M: Augmentation of mouse natural killer cell activity by Lactobacillus casei and its surface antigens. Microbiol Immunol 1984, 27:209-217.
23. Matsuzaki T, Saito M, Usuku K, et al.: Prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. J Neurol Sci 2005, 237:75-81.
24. Oh U, Yamano Y, Mora CA, et al.: Interferon-β1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol 2005, 57:526-534.
25. Lezin A, Gillet N, Olindo S, et al.: Historic deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1-associated myelopathy/tropical spastic paraparesis patients. Blood 2007, 110:3722-3728.
26. Araújo AP, Fontenelle LM, Padua PA, et al.: Juvenile human T lymphotropic virus type 1-associated myelopathy. Clin Infect Dis 2002, 35:201-204.
27. Bittencourt AL, Primo J, Oliveira MF: Manifestations of the human T-cell lymphotropic virus type I infection in childhood and adolescence. J Pediatr (Rio J) 2006, 82:411-420.